Cargando…

Risk Factors and Nomogram for Predicting Relapse Risk in Pediatric Neuromyelitis Optica Spectrum Disorders

BACKGROUND: Neuromyelitis optica spectrum disorders (NMOSDs) are attack-relapsing autoimmune inflammatory diseases of the central nervous system, which are characterized by the presence of serological aquaporin-4 (AQP4) antibody. However, this disorder is uncommon in children, and AQP4 antibody was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Shanchao, Qiao, Shan, Li, Haiyun, Zhang, Ranran, Wang, Meiling, Han, Tao, Liu, Xuewu, Wang, Yunshan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894181/ https://www.ncbi.nlm.nih.gov/pubmed/35250969 http://dx.doi.org/10.3389/fimmu.2022.765839

Ejemplares similares

COVID-19 and the risk of neuromyelitis optica spectrum disorder: a Mendelian randomization study
por: Sun, Dongren, et al.
Publicado: (2023)

Age of onset correlates with clinical characteristics and prognostic outcomes in neuromyelitis optica spectrum disorder
por: Hu, Yacen, et al.
Publicado: (2022)

Visual disability in neuromyelitis optica spectrum disorders: prognostic prediction models
por: Luo, Wenqin, et al.
Publicado: (2023)

Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
por: Ramanathan, Ramnath Santosh, et al.
Publicado: (2014)

Immunopathogenesis in Myasthenia Gravis and Neuromyelitis Optica
por: Wang, Zhen, et al.
Publicado: (2017)

The causal relationship between neuromyelitis optica spectrum disorder and other autoimmune diseases
por: Wang, Xiaofei, et al.
Publicado: (2022)

Relapse of Neuromyelitis Optica Spectrum Disorder Associated with Intravenous Lidocaine
por: Uzawa, Akiyuki, et al.
Publicado: (2011)

Rare variants and HLA haplotypes associated in patients with neuromyelitis optica spectrum disorders
por: Tabansky, Inna, et al.
Publicado: (2022)

Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders
por: Miyamoto, Katsuichi, et al.
Publicado: (2023)

The different damage patterns of short-, middle- and long-range connections between patients with relapse-remitting multiple sclerosis and neuromyelitis optica spectrum disorder
por: Chen, Xiaoya, et al.
Publicado: (2022)

Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models
por: Wang, Liang, et al.
Publicado: (2022)

Thymic Involution and Altered Naive CD4 T Cell Homeostasis in Neuromyelitis Optica Spectrum Disorder
por: Chang, Haoxiao, et al.
Publicado: (2021)

Predictive role of blood-based indicators in neuromyelitis optica spectrum disorders
por: Fang, Xiqin, et al.
Publicado: (2023)

A Comprehensive Review on the Role of Genetic Factors in Neuromyelitis Optica Spectrum Disorder
por: Ghafouri-Fard, Soudeh, et al.
Publicado: (2021)

The Emerging Role of Microglia in Neuromyelitis Optica
por: Chen, Tingjun, et al.
Publicado: (2021)

Neuromyelitis Optica Spectrum Disorder
por: Cazzaniga, Juliana, et al.
Publicado: (2023)

Relapse of neuromyelitis optica associated with oral progestin
por: Li, Li-Min, et al.
Publicado: (2018)

Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder
por: Kessler, Remi A., et al.
Publicado: (2016)

Eculizumab for acute relapse of neuromyelitis optica spectrum disorder: Case report
por: Chatterton, Sophie, et al.
Publicado: (2022)

Early Initiation of Tocilizumab Treatment Against Moderate-to-Severe Myelitis in Neuromyelitis Optica Spectrum Disorder
por: Du, Chen, et al.
Publicado: (2021)

Serum Homocysteine Level Is a Predictor of Relapse and Prognosis in Patients With First-Attack Neuromyelitis Optica Spectrum Disorders
por: Zhang, Jinwei, et al.
Publicado: (2021)

Serum Clusterin and Complement Factor H May Be Biomarkers Differentiate Primary Sjögren's Syndrome With and Without Neuromyelitis Optica Spectrum Disorder
por: Qiao, Lin, et al.
Publicado: (2019)

Therapeutic Response and Possible Biomarkers in Acute Attacks of Neuromyelitis Optica Spectrum Disorders: A Prospective Observational Study
por: Wang, Jingqi, et al.
Publicado: (2021)

Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders
por: Fan, Moli, et al.
Publicado: (2020)

The risk of dementia in multiple sclerosis and neuromyelitis optica spectrum disorder
por: Cho, Eun Bin, et al.
Publicado: (2023)

Elevated cerebrospinal fluid uric acid during relapse of neuromyelitis optica spectrum disorders
por: Shu, Yaqing, et al.
Publicado: (2016)

Research hotspots and trends on neuromyelitis optica spectrum disorders: insights from bibliometric analysis
por: Chen, Xin, et al.
Publicado: (2023)

Triglyceride Level Is an Independent Risk Factor in First-Attacked Neuromyelitis Optica Spectrum Disorders Patients
por: Wu, Kaimin, et al.
Publicado: (2019)

Effects of Tocilizumab Therapy on Circulating B Cells and T Helper Cells in Patients With Neuromyelitis Optica Spectrum Disorder
por: Liu, Ye, et al.
Publicado: (2021)

Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder
por: Nosadini, Margherita, et al.
Publicado: (2016)

Low-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: A Prospective Multicenter Study in South China
por: Huang, Qiao, et al.
Publicado: (2018)

Satralizumab as an add-on treatment in refractory pediatric AQP4-antibody-positive neuromyelitis optica spectrum disorder: a case report
por: Li, Xiaojing, et al.
Publicado: (2023)

Neuromyelitis optica spectrum disorder: pregnancy-related attack and predictive risk factors
por: Wang, Liang, et al.
Publicado: (2021)

The circadian rhythms regulated by Cx43-signaling in the pathogenesis of Neuromyelitis Optica
por: Xue, Huiru, et al.
Publicado: (2023)

Expression and Clinical Correlation Analysis Between Repulsive Guidance Molecule a and Neuromyelitis Optica Spectrum Disorders
por: Tang, Jinhua, et al.
Publicado: (2022)

Neuromyelitis optica spectrum disorders: An update
por: Pandit, Lekha
Publicado: (2015)

Treatment of Neuromyelitis Optica Spectrum Disorders
por: Chan, Koon-Ho, et al.
Publicado: (2021)

Satralizumab for neuromyelitis optica spectrum disorder
Publicado: (2021)

Spectrum of sublytic astrocytopathy in neuromyelitis optica
por: Guo, Yong, et al.
Publicado: (2021)

Autoantibodies Against the Complement Regulator Factor H in the Serum of Patients With Neuromyelitis Optica Spectrum Disorder
por: Uzonyi, Barbara, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_et4qfbs7da3qeh5fam3ugcscrv